Effectiveness of private land conservation areas in maintaining natural land cover and biodiversity intactness

CITATION: Shumba, T. et al. 2020. Effectiveness of private land conservation areas in maintaining natural land cover and biodiversity intactness. Global Ecology and Conservation, 22:e00935, doi:10.1016/j.gecco.2020.e00935.The original publication is available at https://www.journals.elsevier.com/global-ecology-and-conservationPrivate land conservation areas (PLCAs) are increasingly looked to for meeting the deficit left by state-owned protected areas in reaching global conservation targets. However, despite the increasing extent and recognition of PLCAs as a complementary conservation strategy, little research has been done to quantify their effectiveness; a critical consideration if they are to be counted towards international biodiversity conservation targets. The long history of PLCAs in South Africa provides an interesting case study to address this knowledge gap. Here, we quantified the effectiveness of South African PLCAs by comparing losses in natural land cover and biodiversity intactness within PLCAs with different levels of protection to that of unprotected control points. Points within PLCAs were matched with unprotected control points to test the prediction that if PLCAs offer effective protection, losses in natural land cover and biodiversity intactness would be significantly lower within their boundaries in comparison to unprotected controls exposed to similar conditions. Consequences of natural land cover loss on biodiversity intactness were thus assessed, thus advancing standard approaches for quantifying effectiveness. Between 1990 and 2013, PLCAs lost significantly less natural land cover (3%) and biodiversity intactness (2%) than matched unprotected areas (6% and 4%, respectively). Of the natural land cover lost within PLCAs, most was converted to cultivated land. Farms can support more species than other land uses (e.g. mines), a likely explanation for why losses in biodiversity intactness were less than losses in natural land cover. Contrary to the predicted pattern, effectiveness did not increase with level of protection; informal PLCAs with no legal protection had comparable natural land cover and biodiversity intactness retention to strictly protected PLCAs, with most losses recorded among PLCAs with moderate protection. This study provides the first national-scale evidence that PLCAs can be an effective mechanism for conserving natural land cover and biodiversity intactness, which is highly relevant given current discussions around their likely long-term biodiversity conservation capacity.Publisher's versio

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

Predicció de risc de càncer de mama; Dones europees; Variant patògena heterozigotaPredicción del riesgo de cáncer de mama; Mujeres europeas; Variante patógena heterocigotaBreast cancer risk prediction; European women; Heterozygous pathogenic variantPurpose To evaluate the association between a previously published 313 variant–based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes. Methods We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk. Results For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06–1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07–1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively. Conclusion The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer:Chemotherapy or Chemoradiotherapy?

Worldwide, there is a shifting paradigm from immediate surgery with adjuvant treatment to a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer (RPC or BRPC). Comparison of neoadjuvant and adjuvant studies is extremely difficult because of a great difference in patient selection. The evidence from randomized studies shows that overall survival by intention-to-treat improves after neoadjuvant gemcitabine-based chemoradiotherapy or chemotherapy (various regimens), as compared to immediate surgery followed by adjuvant chemotherapy. Radiotherapy appears to play an important role in mediating locoregional effects. Yet, since more effective chemotherapy regimens are currently available, in particular FOLFIRINOX and Gemcitabine/Nab-paclitaxel, these chemotherapy regimens should be investigated in future randomized trials combined with (stereotactic) radiotherapy to further improve outcomes of RPC and BRPC

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs)